Corn Goes Pop, Then Kaboom

On April 4, Nature sent ripples through the scientific community and the popular press by admitting it made a mistake. In an unprecedented action, editor Philip Campbell concluded in the journal's online version that "evidence available is not sufficient to justify publication" of a paper that appeared in the Nov. 29, 2001 issue. It wasn't exactly a retraction, but it was close. Along with its statement, Nature published two rebuttals to the original paper, plus a response from authors David Qui

Written byBarry Palevitz
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

The April 4 online announcement, then publication in print April 11, was the latest in a series of skirmishes that started before the Nov. 29 issue appeared. Using PCR to detect a DNA signature diagnostic of genetic engineering, Quist and Chapela claimed that biotech transgenes had invaded so-called land races of maize planted by local farmers in Mexico, probably via cross pollination.2 The researchers said the promiscuous sequences probably entered the maize genome many times and even fragmented—claims that set off alarm bells in plant molecular biology laboratories.

It didn't take long before the molecular biology community responded officially. By mid-December, Nature received at least two letters to the editor in rebuttal; one from a collaboration between groups in UC-Berkeley's department of plant and microbial biology and the Plant Gene Expression Center in nearby Albany, Calif., and another joint response from British Columbia and the University of Georgia in Athens. ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies